Voyager Reports Third Quarter 2025 Financial and Operating Results

Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with ...
CoinTelegraph

Fed demands Voyager remove ‘false’ claims deposits are FDIC insured

Crypto lender Voyager Digital has been directed to remove “false and misleading” statements that its user’s deposit accounts are FDIC insured. In a joint letter written on Thursday by Seth Rosebrock ...
Nasdaq

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene ...

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid ...
Seeking Alpha

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene ...

- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial ...
Crowdfund Insider

CFTC Files Charges Against Voyager Digital CEO, Alleges Massive Fraud

Voyager Digital, now bankrupt as part of the crypto collapse of 2022, is in the news once again as the Commodities Futures Trading Commission (CFTC) has filed charges against its former CEO, Stephen ...
Seeking Alpha

Voyager Reports First Quarter 2025 Financial and Operating Results

– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – ...